MANGALAM DRUGS & ORGANICS LTD.

Mangalam Drugs & Organics Ltd has officially informed the stock exchanges about its default on loan obligations to Bank of Baroda and Bank of Maharashtra. The company has exceeded the 30-day grace period for non-payment of interest or principal. Specifically, the default pertains to a Cash Credit A/c with Bank of Maharashtra for ₹951.19 Lacs (₹9.51 Crore) and with Bank of Baroda for ₹606.08 Lacs (₹6.06 Crore). The company stated it is making arrangements to pay the overdue amounts as soon as possible. This filing is a subsequent intimation regarding the bank default as per SEBI (LODR) Regulations, 2015.

Mangalam Drugs & Organics Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut for all designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ended September 30, 2026. This measure is standard practice to prevent insider trading during the sensitive period of financial result announcement.

Mangalam Drugs & Organics Limited announced at its 53rd AGM that M/s L.N. Joshi & Co. has been appointed as Secretarial Auditors and M/s S.N. Nanda & Co. as Statutory Auditors. Both appointments are for a period of five consecutive years, commencing from the conclusion of the 53rd AGM up to the 58th AGM. This move follows the retirement of the previous Statutory Auditor, M/s V.S. Somani and Co., upon completion of their term. The company has complied with SEBI (LODR) Regulations, 2015 for these appointments.

Mangalam Drugs & Organics Ltd announced the appointment of M/s S. N Nanda & Co, Chartered Accountants, as its Statutory Auditor for a period of five consecutive years. This appointment was approved by the shareholders at the 53rd General Meeting held on September 23, 2026. The firm has over 60 years of experience in auditing public sector undertakings, banks, and other organizations. Concurrently, M/s L.N. Joshi & Co. was appointed as Secretarial Auditors for the same term, and M/s V.S. Somani and Co. retired as Statutory Auditors upon completion of their term.

Mangalam Drugs & Organics Ltd has informed the stock exchanges that M/s V.S. Somani and Co., Chartered Accountants, have retired as the company's Statutory Auditor upon completion of their term. The company's members approved the appointment of M/s S.N. Nanda & Co. as the new Statutory Auditor for a period of five years, from the conclusion of the 53rd AGM to the 58th AGM. Additionally, M/s L.N. Joshi & Co. has been appointed as the Secretarial Auditor for the same five-year tenure.

Mangalam Drugs & Organics Ltd has officially disclosed a default on its loan obligations to Bank of Baroda and Bank of Maharashtra. The company has exceeded the 30-day grace period for repayment on two cash credit accounts. The total overdue amount is ₹1557.27 Lakhs, with ₹951.19 Lakhs owed to Bank of Maharashtra and ₹606.08 Lakhs to Bank of Baroda. The company states it is making arrangements to pay the overdue amounts as soon as possible.

Mangalam Drugs & Organics Ltd announced the appointment of Mr. Prabhakar Raghunath Zavar as an Additional Independent Non-Executive Director. The appointment is for a term of five consecutive years, effective September 15, 2026, and is subject to shareholder approval at the upcoming Extra-Ordinary General Meeting. Mr. Zavar brings over 38 years of experience in Accounts, Finance, and Taxation, with expertise in export-oriented businesses and diversified client services. He is not related to any existing directors of the company. The board meeting where this was approved commenced at 2:30 PM and concluded at 3:25 PM on September 15, 2026.

Mangalam Drugs & Organics Ltd announced the appointment of Mr. Prabhakar Raghunath Zavar as an Additional Independent Non-Executive Director. The appointment is for a term of five years, effective September 15, 2026, and is subject to shareholder approval at the upcoming Extra-Ordinary General Meeting. Mr. Zavar brings over 38 years of experience in Accounts, Finance, and Taxation, with expertise in export-oriented businesses and diversified client services. He is not related to any existing directors of the company.

Mangalam Drugs & Organics Ltd has announced the dispatch of its Annual Report for the financial year 2025-26, along with the notice convening the 53rd Annual General Meeting (AGM). The AGM is scheduled for Wednesday, September 23rd, 2026, at 03:00 PM IST, to be held via Video Conference/Other Audio-Visual Means. The report and notice are being sent electronically to shareholders. The cut-off date for e-voting is September 16, 2026, with e-voting commencing on September 19, 2026, and concluding on September 22, 2026. The Annual Report is also available on the company's website and NSDL's e-voting portal.

Mangalam Drugs & Organics Ltd has announced its 53rd Annual General Meeting (AGM) for the financial year 2025-26, scheduled for Wednesday, September 23rd, 2026, at 3:00 PM IST. The meeting will be conducted through Video Conference/Other Audio-Visual Means. The company has also intimated the cut-off date for e-voting as September 16, 2026. The Annual Report for FY 2025-26, including the AGM notice, has been dispatched electronically to members and is available on the company's website and NSDL's e-voting portal. The filing also details changes in Key Managerial Personnel and auditors.